Literature DB >> 33740980

Establishment and characterization of HXWMF-1: the first mouse fibroblastic tumor cell line derived from leukemia-associated fibroblasts.

Yuanyuan Li1,2, Ling Gu3,4.   

Abstract

BACKGROUND: Chemo-resistance is still a major obstacle in leukemia treatment. Accumulating evidence indicates that cancer-associated fibroblasts (CAFs), the most abundant stromal cells in tumor microenvironment (TME), play a crucial role in cancer progression and response to chemotherapy. To Figure out the role of leukemia-associated fibroblasts (LAFs) in relapsed/refractory leukemia, we constructed the first leukemia-associated fibroblastic tumor cell line, HXWMF-1.
METHODS: A cell culture technique was used to establish the leukemia-associated fibroblastic tumor cell line. Molecular and cellular biological techniques including flow cytometry, MTT assay, western blotting, and short tandem repeat (STR) analysis were used to characterize the cell line. Nude mice were used for xenograft studies.
RESULTS: We established a LAFs derived tumor cell line HXWMF-1, originated from the subcutaneous xenografts of HXEX-ALL1, a cell line originated from a patient with acute lymphoblastic leukemia (ALL) at the second relapse. The HXWMF-1 cell line was authenticated as a tumor cell line and being derived from CAFs based on morphologic, immunophenotypic, cytogenetic and STR analyses and tumorigenicity test in nude mice. To clarify the reliability of the method, we got the LAFs derived tumor cells from three different tumor mass of HXEX-ALL1 xenografts.
CONCLUSIONS: To our knowledge, HXWMF-1 is the first fibroblastic tumor cell line derived from LAFs or CAFs. In addition, the cell line provided firm evidence for that leukemia cells may induce LAFs/CAFs malignant transformation, which may help to develop brand new theory and therapeutic strategies for patients with relapsed /refractory ALL.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Cancer-associated fibroblasts; Cell line; Leukemic environment

Year:  2021        PMID: 33740980     DOI: 10.1186/s12935-021-01870-7

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  41 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 3.  Haematopoietic stem cell activity and interactions with the niche.

Authors:  Sandra Pinho; Paul S Frenette
Journal:  Nat Rev Mol Cell Biol       Date:  2019-05       Impact factor: 94.444

4.  Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas.

Authors:  Allison R Pine; Stefano M Cirigliano; James G Nicholson; Yang Hu; Amanda Linkous; Ken Miyaguchi; Lincoln Edwards; Richa Singhania; Theodore H Schwartz; Rohan Ramakrishna; David J Pisapia; Matija Snuderl; Olivier Elemento; Howard A Fine
Journal:  Cancer Discov       Date:  2020-04-06       Impact factor: 39.397

Review 5.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

Review 6.  How I treat relapsed acute lymphoblastic leukemia in the pediatric population.

Authors:  Stephen P Hunger; Elizabeth A Raetz
Journal:  Blood       Date:  2020-10-15       Impact factor: 22.113

7.  Tumor-initiating cells establish an IL-33-TGF-β niche signaling loop to promote cancer progression.

Authors:  Sachiko Taniguchi; Ajit Elhance; Avery Van Duzer; Sushil Kumar; Justin J Leitenberger; Naoki Oshimori
Journal:  Science       Date:  2020-07-17       Impact factor: 47.728

Review 8.  Relapsed childhood acute lymphoblastic leukaemia.

Authors:  Deepa Bhojwani; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

Review 9.  Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.

Authors:  David T Teachey; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2019-03       Impact factor: 54.433

Review 10.  Precision medicine in acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui
Journal:  Front Med       Date:  2020-10-19       Impact factor: 9.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.